Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04−1.16 (-36.25%)
Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –
Kyntra Bio r&d expenses
Research and development expenses are spending on new products and technology.
Kyntra Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.86M, down 45.4% year over year. For fiscal 2025 it was $23.52M, down 75.4% from the year before. Over ten years it grew -19.8% a year on average. The highest annual figure on record is $387.04M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.52M | -75.4% |
| FY2024 | Dec 31, 2024 | $95.69M | -64.1% |
| FY2023 | Dec 31, 2023 | $266.47M | -10.2% |
| FY2022 | Dec 31, 2022 | $296.79M | -23.3% |
| FY2021 | Dec 31, 2021 | $387.04M | +53.0% |
| FY2020 | Dec 31, 2020 | $252.92M | +20.9% |
| FY2019 | Dec 31, 2019 | $209.27M | -11.3% |
| FY2018 | Dec 31, 2018 | $235.84M | +20.0% |
| FY2017 | Dec 31, 2017 | $196.52M | +5.0% |
| FY2016 | Dec 31, 2016 | $187.21M | -12.6% |
| FY2015 | Dec 31, 2015 | $214.09M | +42.0% |
| FY2014 | Dec 31, 2014 | $150.79M | +75.9% |
| FY2013 | Dec 31, 2013 | $85.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.82M | +16.3% |
| Q1 FY2026 | Mar 31, 2026 | $7.57M | -17.5% |
| Q4 FY2025 | Dec 31, 2025 | $7.27M | +5.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.21M | -93.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.87M | -81.9% |
| Q1 FY2025 | Mar 31, 2025 | $9.18M | -74.9% |
| Q4 FY2024 | Dec 31, 2024 | $6.87M | -80.6% |
| Q3 FY2024 | Sep 30, 2024 | $19.97M | -67.4% |
| Q2 FY2024 | Jun 30, 2024 | $32.36M | -66.1% |
| Q1 FY2024 | Mar 31, 2024 | $36.49M | -51.0% |
| Q4 FY2023 | Dec 31, 2023 | $35.32M | -42.7% |
| Q3 FY2023 | Sep 30, 2023 | $61.19M | -18.6% |
| Q2 FY2023 | Jun 30, 2023 | $95.48M | +34.5% |
| Q1 FY2023 | Mar 31, 2023 | $74.49M | -16.3% |
| Q4 FY2022 | Dec 31, 2022 | $61.63M | -45.9% |
| Q3 FY2022 | Sep 30, 2022 | $75.18M | -0.9% |
| Q2 FY2022 | Jun 30, 2022 | $70.96M | -42.1% |
| Q1 FY2022 | Mar 31, 2022 | $89.02M | +19.2% |
| Q4 FY2021 | Dec 31, 2021 | $113.92M | +45.8% |
| Q3 FY2021 | Sep 30, 2021 | $75.88M | +29.8% |
| Q2 FY2021 | Jun 30, 2021 | $122.57M | +99.6% |
| Q1 FY2021 | Mar 31, 2021 | $74.68M | +36.0% |
| Q4 FY2020 | Dec 31, 2020 | $78.13M | +37.6% |
| Q3 FY2020 | Sep 30, 2020 | $58.48M | +17.0% |
| Q2 FY2020 | Jun 30, 2020 | $61.41M | +18.1% |
| Q1 FY2020 | Mar 31, 2020 | $54.90M | +8.7% |
| Q4 FY2019 | Dec 31, 2019 | $56.80M | -19.2% |
| Q3 FY2019 | Sep 30, 2019 | $49.96M | -11.5% |
| Q2 FY2019 | Jun 30, 2019 | $52.01M | -0.2% |
| Q1 FY2019 | Mar 31, 2019 | $50.50M | -11.4% |
| Q4 FY2018 | Dec 31, 2018 | $70.28M | +34.0% |
| Q3 FY2018 | Sep 30, 2018 | $56.44M | +12.1% |
| Q2 FY2018 | Jun 30, 2018 | $52.14M | +11.0% |
| Q1 FY2018 | Mar 31, 2018 | $56.97M | +21.9% |
| Q4 FY2017 | Dec 31, 2017 | $52.47M | +3.7% |
| Q3 FY2017 | Sep 30, 2017 | $50.34M | +24.1% |
| Q2 FY2017 | Jun 30, 2017 | $46.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $46.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $50.61M | – |
| Q3 FY2016 | Sep 30, 2016 | $40.56M | – |
See a number that looks wrong?